Anaptysbio (ANAB) Assets (2016 - 2026)

Anaptysbio has reported Assets for 11 years, with the latest figure at $329.7 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 21.89% year-over-year to $329.7 million; the trailing twelve-month figure through Mar 2026 stood at $329.7 million (down 21.89% YoY), and the FY2025 full-year result was $364.4 million, down 24.69% from the prior year.
• Assets for Q1 2026 stood at $329.7 million, down from $364.4 million in the prior quarter.
• The five-year high for Assets was $625.2 million in Q1 2022, with the low at $329.7 million in Q1 2026.
• Historically, Assets has averaged $475.4 million across 5 years, with a median of $483.8 million in 2024.
• Annual changes were most pronounced in 2022 — Assets soared 57.7% — and 2025, when it dropped 28.44%.
• Anaptysbio's Assets stood at $610.4 million in 2022, then fell by 25.88% to $452.4 million in 2023, then grew by 6.95% to $483.8 million in 2024, then retreated by 24.69% to $364.4 million in 2025, then retreated by 9.53% to $329.7 million in 2026.
• The last three Assets figures came in at $329.7 million (Q1 2026), $364.4 million (Q4 2025), and $353.1 million (Q3 2025), per Business Quant data.